PD-L1 expression in NK/T cell lymphoma has been reported to be 56–93% in various studies and this has stirred excitement in the use of PD-1/PD-L1 inhibitors in NKTL [19, 32–34]. This evidence concerns the gene CD274 and T-cell non-Hodgkin lymphoma.